A detailed history of Gsa Capital Partners LLP transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 285,588 shares of BCRX stock, worth $2.08 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
285,588
Previous 363,838 21.51%
Holding current value
$2.08 Million
Previous $2.25 Million 3.51%
% of portfolio
0.16%
Previous 0.16%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$6.41 - $8.69 $501,582 - $679,992
-78,250 Reduced 21.51%
285,588 $2.17 Million
Q2 2024

Aug 15, 2024

BUY
$4.13 - $6.79 $1.5 Million - $2.47 Million
363,838 New
363,838 $2.25 Million
Q4 2023

Feb 16, 2024

SELL
$4.98 - $6.77 $63,534 - $86,371
-12,758 Reduced 6.66%
178,769 $1.07 Million
Q3 2023

Nov 15, 2023

BUY
$6.71 - $7.92 $805,166 - $950,360
119,995 Added 167.75%
191,527 $1.36 Million
Q2 2023

Aug 14, 2023

SELL
$6.96 - $8.81 $572,014 - $724,058
-82,186 Reduced 53.47%
71,532 $503,000
Q1 2023

May 12, 2023

BUY
$7.94 - $11.84 $1.22 Million - $1.82 Million
153,718 New
153,718 $1.28 Million
Q3 2022

Nov 14, 2022

BUY
$10.79 - $14.81 $206,315 - $283,182
19,121 New
19,121 $241,000
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $459,676 - $635,653
-41,116 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$14.21 - $17.65 $584,258 - $725,697
41,116 New
41,116 $591,000
Q2 2021

Aug 05, 2021

SELL
$9.5 - $17.24 $761,871 - $1.38 Million
-80,197 Closed
0 $0
Q1 2021

May 10, 2021

BUY
$7.37 - $13.61 $513,666 - $948,576
69,697 Added 663.78%
80,197 $816,000
Q4 2020

Feb 03, 2021

BUY
$3.37 - $8.61 $35,385 - $90,405
10,500 New
10,500 $78,000
Q3 2020

Nov 06, 2020

SELL
$3.43 - $5.53 $135,824 - $218,982
-39,599 Closed
0 $0
Q2 2020

Aug 11, 2020

SELL
$1.9 - $5.61 $188,223 - $555,754
-99,065 Reduced 71.44%
39,599 $189,000
Q1 2020

May 12, 2020

BUY
$1.6 - $4.11 $221,862 - $569,909
138,664 New
138,664 $277,000
Q2 2019

Aug 06, 2019

SELL
$2.91 - $9.15 $117,514 - $369,504
-40,383 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$7.38 - $9.72 $298,026 - $392,522
40,383 New
40,383 $329,000
Q4 2017

Feb 14, 2018

SELL
$4.16 - $5.33 $54,437 - $69,748
-13,086 Closed
0 $0
Q3 2017

Nov 20, 2017

BUY
$4.1 - $5.97 $53,652 - $78,123
13,086
13,086 $69,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.36B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.